Total Payments
$673,747
2024 Payments
$77,706
Companies
26
Transactions
1,382
Medicare Patients
328
Medicare Billing
$38,985
Payment Breakdown by Category
Other$525,634 (78.0%)
Travel$80,307 (11.9%)
Consulting$31,861 (4.7%)
Food & Beverage$29,411 (4.4%)
Research$4,995 (0.7%)
Education$1,539 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $513,284 | 205 | 76.2% |
| Travel and Lodging | $80,307 | 247 | 11.9% |
| Consulting Fee | $31,861 | 12 | 4.7% |
| Food and Beverage | $29,411 | 856 | 4.4% |
| Honoraria | $12,350 | 7 | 1.8% |
| Unspecified | $4,995 | 44 | 0.7% |
| Education | $1,539 | 11 | 0.2% |
Payments by Type
General
$668,753
1,338 transactions
Research
$4,995
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Products, LP | $362,410 | 374 | $0 (2023) |
| ViiV Healthcare Company | $234,373 | 390 | $0 (2024) |
| Merck Sharp & Dohme LLC | $43,010 | 158 | $0 (2024) |
| Theratechnologies Inc. | $19,325 | 58 | $0 (2024) |
| Gilead Sciences, Inc. | $7,358 | 114 | $0 (2024) |
| Janssen Biotech, Inc. | $3,021 | 198 | $0 (2023) |
| AbbVie Inc. | $2,825 | 42 | $0 (2023) |
| Napo Pharmaceuticals Inc | $324.72 | 10 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $266.88 | 5 | $0 (2023) |
| Dynavax Technologies Corporation | $132.09 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $77,706 | 130 | ViiV Healthcare Company ($56,933) |
| 2023 | $122,134 | 239 | ViiV Healthcare Company ($69,957) |
| 2022 | $123,064 | 179 | Janssen Products, LP ($72,050) |
| 2021 | $36,241 | 81 | ViiV Healthcare Company ($24,869) |
| 2020 | $30,901 | 85 | Janssen Products, LP ($17,700) |
| 2019 | $124,936 | 279 | Janssen Products, LP ($78,518) |
| 2018 | $74,094 | 201 | Janssen Products, LP ($70,296) |
| 2017 | $84,671 | 188 | Janssen Products, LP ($82,351) |
All Payment Transactions
1,382 individual payment records from CMS Open Payments — Page 1 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $34.36 | General |
| Category: HIV | ||||||
| 12/17/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: HIV | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.14 | General |
| 12/10/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $117.52 | General |
| 12/10/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: HIV | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,255.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Travel and Lodging | Cash or cash equivalent | $32.24 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/02/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: HIV | ||||||
| 11/26/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $48.72 | General |
| Category: HIV | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,255.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $82.16 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/19/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/08/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Travel and Lodging | Cash or cash equivalent | $162.00 | General |
| Category: HIV | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Food and Beverage | In-kind items and services | $122.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/29/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $31.84 | General |
| Category: HIV | ||||||
| 10/29/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: HIV | ||||||
| 10/22/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $42.91 | General |
| Category: HIV | ||||||
| 10/17/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 10/17/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Travel and Lodging | In-kind items and services | $785.96 | General |
| Category: HIV | ||||||
| 10/17/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Travel and Lodging | In-kind items and services | $162.58 | General |
| Category: HIV | ||||||
| 10/17/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $115.66 | General |
| Category: HIV | ||||||
| 10/17/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $27.95 | General |
| 10/15/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: HIV | ||||||
| 10/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,454 | 8 |
| A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | AbbVie Inc. | $1,360 | 9 |
| M19-939 | AbbVie Inc. | $953.58 | 11 |
| A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | ViiV Healthcare Company | $950.76 | 10 |
| A QUALITATIVE HYBRID III IMPLEMENTATION STUDY TO IDENTIFY AND EVALUATE | ViiV Healthcare Company | $173.37 | 3 |
| A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | Gilead Sciences, Inc. | $102.42 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 34 | 85 | $12,750 | $6,474 |
| 2022 | 5 | 94 | 168 | $40,787 | $10,427 |
| 2021 | 5 | 116 | 195 | $60,547 | $14,308 |
| 2020 | 4 | 84 | 136 | $17,916 | $7,776 |
Total Patients
328
Total Services
584
Medicare Billing
$38,985
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 34 | 85 | $12,750 | $6,474 | 50.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 100 | $35,328 | $7,199 | 20.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 17 | 22 | $3,583 | $1,713 | 47.8% |
| 0064A | Adm sarscov2 50mcg/0.25mlbst | Office | 2022 | 16 | 19 | $950.00 | $759.87 | 80.0% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2022 | 11 | 13 | $570.24 | $404.43 | 70.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 11 | 14 | $355.36 | $350.36 | 98.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 50 | 116 | $53,657 | $10,102 | 18.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 21 | 32 | $5,332 | $2,934 | 55.0% |
| 90674 | Vaccine for influenza derived from cell cultures for administration into muscle, 0.5 ml dosage, quadrivalent, , preservative and antibiotic free | Office | 2021 | 15 | 16 | $480.96 | $476.91 | 99.2% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 11 | 11 | $550.00 | $448.69 | 81.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 19 | 20 | $526.80 | $345.75 | 65.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 72 | $11,648 | $4,795 | 41.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 19 | 28 | $3,215 | $1,444 | 44.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 12 | 15 | $2,500 | $1,196 | 47.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 18 | 21 | $553.14 | $340.38 | 61.5% |
About Dr. Gary Sinclair, MD
Dr. Gary Sinclair, MD is a Infectious Disease healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891757613.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Sinclair, MD has received a total of $673,747 in payments from pharmaceutical and medical device companies, with $77,706 received in 2024. These payments were reported across 1,382 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($513,284).
As a Medicare-enrolled provider, Sinclair has provided services to 328 Medicare beneficiaries, totaling 584 services with total Medicare billing of $38,985. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Internal Medicine
- Location Dallas, TX
- Active Since 04/05/2006
- Last Updated 04/10/2024
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1891757613
Products in Payments
- CABENUVA (Biological) $136,802
- SYMTUZA (Drug) $132,660
- PREZCOBIX (Drug) $82,482
- Symtuza (Drug) $82,244
- APRETUDE (Biological) $47,991
- DOVATO (Drug) $35,527
- DELSTRIGO (Drug) $19,576
- PIFELTRO (Drug) $15,799
- EGRIFTA SV (Drug) $8,557
- TROGARZO (Drug) $5,853
- TIVICAY (Drug) $3,735
- EGRIFTA (Drug) $2,915
- Biktarvy (Drug) $1,272
- ISENTRESS (Drug) $988.30
- TRIUMEQ (Drug) $626.10
- JULUCA (Drug) $605.13
- Mavyret (Drug) $343.96
- Mytesi (Drug) $324.72
- PREZISTA (Drug) $132.79
- Heplisav-B (Drug) $132.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Dallas
Elizabeth Race, Md, MD
Infectious Disease — Payments: $1.7M
Infectious Disease $1.7M
Han Schmidly
Infectious Disease — Payments: $548,373
Infectious Disease $548,373
Dr. Edward Dominguez, M.d, M.D
Infectious Disease — Payments: $309,485
Infectious Disease $309,485
Dr. Roger Bedimo, M.d, M.D
Infectious Disease — Payments: $276,484
Infectious Disease $276,484
Christopher Bettacchi, Md, MD
Infectious Disease — Payments: $198,393
Infectious Disease $198,393
Dr. Jason Gillman, Md, MD
Infectious Disease — Payments: $61,274
Infectious Disease $61,274